AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 33.4% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 33.5% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 38.4% according to JP Morgan.AZN.LJP Morgan set a target price of 14,000 GBX for the company, which when compared..
AstraZeneca plc (LON:AZN) Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that..
AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -12.4% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 16.3% according to Berenberg Bank.AZN.LBerenberg Bank set a target price of 15,000 GBX for the company, which when compared..
AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -11.1% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -12.0% according to Deutsche.AZN.LDeutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential downside of -10.1% according to Jefferies.AZN.LJefferies set a target price of 11,300 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) has revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth..
